Currently Viewing:
AMCP 2017
Analyzing the Near-Term Pipeline for Specialty Drugs
March 28, 2017
Dr Aimee Tharaldson Highlights Two Key Drugs for 2017
March 28, 2017
Effectively Moving Toward Value-Based Care
March 28, 2017
Susan A. Cantrell on the Evolution of Value Frameworks
March 28, 2017
Dr Liz Zhou Explains Basal Insulin Switching Study on Toujeo
March 28, 2017
Dr Richard Willke on Using Real-World Data to Inform Value-Based Contracts
March 29, 2017
The Unsustainably Big Business of Healthcare
March 29, 2017
Dr Matthew Pickering: How Quality Measures Are Created and Implemented
March 29, 2017
Addressing the Affordability Issue of Novel Treatments
March 29, 2017
Dr Clifford Goodman Outlines Takeaways From a Health Economic Case Study on Repatha
March 30, 2017
Dr Doug Hillblom on the State of e-Prescribing and Remaining Barriers
March 30, 2017
Cardiovascular Outcome Trials: How Misinterpretation of Statistics Can Affect Clinical Practice
March 30, 2017
Repatha Offers Additional LDL-C Reduction in a Convenient Dosage Form
March 30, 2017
ACA Repeal and Other Healthcare Issues on the Trump Administration's Agenda
April 03, 2017
The Latest in the Move to Value-Based Reimbursement and Remaining Challenges
April 04, 2017
Susan Cantrell: Uncertainty Is Affecting Everyone in Healthcare
April 11, 2017
Currently Reading
Dr Aimee Tharaldson Discusses 2 New Treatments for Tardive Dyskinesia
April 12, 2017
Dr Richard Willke Previews ISPOR 2017 in Boston
April 18, 2017
Dr Matthew Pickering Discusses Development, Implementation of Quality Measures
April 20, 2017
Dr Doug Hillblom Expects Evolution of e-Prescribing to Continue
April 22, 2017
Dr Aimee Tharaldson: We're Keeping an Eye on Future NASH Treatments
April 27, 2017
Susan A. Cantrell Outlines Concerns and Opportunities for Managed Care
May 01, 2017
The Importance of Ethical Committees in the Evolving Healthcare Environment
May 11, 2017
Dr Lou Garrison on the Discussions Surrounding Outcomes-Based Arrangements
May 17, 2017

Dr Aimee Tharaldson Discusses 2 New Treatments for Tardive Dyskinesia

The market for tardive dyskinesia, a movement disorder affecting 500,000 patients in the United States, will go from zero approved treatments to 2 in 2017, making it an important area to watch, said Aimee Tharaldson, PharmD, senior clinical consultant for emerging therapeutics at Express Scripts.


The market for tardive dyskinesia, a movement disorder affecting 500,000 patients in the United States, will go from zero approved treatments to 2 in 2017, making it an important area to watch, said Aimee Tharaldson, PharmD, senior clinical consultant for emerging therapeutics at Express Scripts.

Transcript

Is there a disease or a new drug category that payers aren't paying enough attention to?

I think tardive dyskinesia is one area that maybe a lot of payers aren't thinking about right now. Right now there are 2 drugs that are pending approval for tardive dyskinesia [Editor note: the first was approved on April 11, 2017].

So this is a condition where there's abnormal, repetitive movements. And right now there's nothing approved to treat these patients. It can be caused from high doses of dopamine, blocking agents, and chronic use of these medications. And there's about 500,000 patients in the United States that have tardive dyskinesia. Right now, Xenazine is sometimes used off label. It's a 3 times daily medication. It's only approved for Huntington's disease chorea, so that's an orphan condition. Xenazine can cause depression and suicidal ideation, so there's a lot of safety concerns with it.

But there are 2 drugs that are going to be approved for tardive dyskinesia this year, which affects 500,000 patients in the US. Ingrezza will be the first one, that's once daily, and that's expected to be approved April 11. And then Austedo, it's initially going to be approved for Huntington's disease chorea [Editor's note: it was approved April 5, 2017], that orphan condition. But it is pending approval for tardive dyskinesia, as well. So that expanded indication could occur sometime in August of this year.

So we'll have 2 new drugs for tardive dyskinesia, large patient population. It will be interesting to see how much these medications cost. Right now, for Huntington's disease, Xenazine is about $150,000 per year, but you know as the population broadens significantly with these 2 new medications it will be interesting to see how they're priced. So those are important ones to watch.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!